Related Experiment Video

Updated: Jun 30, 2026

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

[Lung diseases associated with inherited disorders of surfactant metabolism]

R Epaud1, D Feldmann, L Guillot

  • 1Pneumologie pédiatrique, hôpital Armand-Trousseau, AP-HP, université Pierre-et-Marie-Curie Paris-6, 75571 Paris, France. ralph.epaud@trs.aphp.fr

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|September 23, 2008
PubMed

Insights

Rare lung diseases linked to surfactant metabolism disorders cause respiratory issues. Mutations in surfactant proteins (SP-B, SP-C) and related genes (ABCA3, TTF-1) are identified in affected infants and children.

Area of Science:

  • Pulmonary Medicine
  • Genetics
  • Rare Diseases

Background:

  • Surfactant metabolism disorders cause rare lung diseases characterized by intra-alveolar protein accumulation.
  • Symptoms include cough, hypoxemia, and diffuse radiological infiltration.
  • Pulmonary surfactant protein B (SP-B) deficiency was first identified in neonates with respiratory failure.

Purpose of the Study:

  • To review current knowledge on lung diseases associated with surfactant metabolism disorders.
  • To highlight genetic mutations affecting surfactant proteins and their clinical manifestations.

Main Methods:

  • Literature review of inherited surfactant protein deficiencies.
  • Analysis of genetic mutations in SP-B, SP-C, ABCA3, and TTF-1.
  • Clinical data synthesis for affected neonates and children.

Main Results:

  • Mutations in SP-B, SP-C, ABCA3, and TTF-1 are implicated in neonatal respiratory distress and chronic childhood pneumonia.
  • These genetic defects disrupt normal surfactant function, leading to lung disease.

Conclusions:

  • Genetic mutations in surfactant proteins and related genes represent a significant cause of rare lung diseases.
  • Early identification and understanding of these disorders are crucial for patient management.

More Related Videos

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome (ARDS)06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome (ARDS)

Published on: April 7, 2021

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome (ARDS)07:20

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome (ARDS)

Published on: September 7, 2016

Related Concept Videos

Breathing01:05

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.